Cargando…

Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report

Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Linghui, Wang, Yue, Lu, Wenbin, Liu, Qian, Wu, Jie, Jin, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359124/
https://www.ncbi.nlm.nih.gov/pubmed/28352185
http://dx.doi.org/10.2147/OTT.S126471
_version_ 1782516332662620160
author Deng, Linghui
Wang, Yue
Lu, Wenbin
Liu, Qian
Wu, Jie
Jin, Jianhua
author_facet Deng, Linghui
Wang, Yue
Lu, Wenbin
Liu, Qian
Wu, Jie
Jin, Jianhua
author_sort Deng, Linghui
collection PubMed
description Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for patients with ovarian cancer. Here, we present the case of a 50-year-old Chinese woman with advanced ovarian cancer, who received apatinib at a daily dose of 500 mg for 28 days per cycle after failure of fourth-line chemotherapy. Favorable oncologic outcome was achieved in this case after treatment with apatinib. The patient’s progression-free survival is now 11.3 months, and she is taking apatinib and capecitabine as maintenance treatment. The common side effect of apatinib was fatigue; however, the toxicity of apatinib was controllable and tolerable. Thus, apatinib may be an option for chemotherapy-refractory advanced epithelial ovarian cancer, but this still warrants further investigation.
format Online
Article
Text
id pubmed-5359124
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53591242017-03-28 Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report Deng, Linghui Wang, Yue Lu, Wenbin Liu, Qian Wu, Jie Jin, Jianhua Onco Targets Ther Case Report Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for patients with ovarian cancer. Here, we present the case of a 50-year-old Chinese woman with advanced ovarian cancer, who received apatinib at a daily dose of 500 mg for 28 days per cycle after failure of fourth-line chemotherapy. Favorable oncologic outcome was achieved in this case after treatment with apatinib. The patient’s progression-free survival is now 11.3 months, and she is taking apatinib and capecitabine as maintenance treatment. The common side effect of apatinib was fatigue; however, the toxicity of apatinib was controllable and tolerable. Thus, apatinib may be an option for chemotherapy-refractory advanced epithelial ovarian cancer, but this still warrants further investigation. Dove Medical Press 2017-03-13 /pmc/articles/PMC5359124/ /pubmed/28352185 http://dx.doi.org/10.2147/OTT.S126471 Text en © 2017 Deng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Deng, Linghui
Wang, Yue
Lu, Wenbin
Liu, Qian
Wu, Jie
Jin, Jianhua
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
title Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
title_full Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
title_fullStr Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
title_full_unstemmed Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
title_short Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
title_sort apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359124/
https://www.ncbi.nlm.nih.gov/pubmed/28352185
http://dx.doi.org/10.2147/OTT.S126471
work_keys_str_mv AT denglinghui apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport
AT wangyue apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport
AT luwenbin apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport
AT liuqian apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport
AT wujie apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport
AT jinjianhua apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport